Please assess the completion status of the following clinical trial:

Trial Title: Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed non-metastatic infiltrating carcinoma of the breast.~2. HER-2 amplified (FISH +) determination in 2004 or thereafter.~3. ECOG performance status 0-2.~4. Patients 18 years of age or older.~5. HER-2 status is determined by FISH test.~6. The following criteria are applicable to the trastuzumab treatment group:~   * Normal LVEF as determined by ECHO or MUGA. If baseline LVEF \> 75%, then LVEF shall be repeated to determine if falsely elevated.~  * Adequate bone marrow function as indicated by the following: ANC \>1500/mL, Platelets \>/=100,000/mL, Hemoglobin \>9 g/dL~  * Adequate renal function,as indicated by serum creatinine \</= 1.5 x ULN~  * Adequate liver function, as indicated by total bilirubin \</= 1.5 x ULN~  * AST and ALT \< 2 x ULN unless related to primary disease.~  * If female of childbearing potential, pregnancy test (blood or urine) is negative and she agrees to use effective birth control method for the duration of the study.~7. Signed informed consent has been obtained.~Exclusion Criteria:~1. Non-confirmed HER-2 positive by FISH infiltrating carcinoma of the breast.~2. Evidence of metastatic disease.~3. Previous trastuzumab treatment.~4. Concurrent anticancer treatment other than hormonal agents (tamoxifen, aromatase inhibitors) or radiotherapy.~5. Patient with history of or active cardiac disease, including cardiomyopathy, congestive heart failure, prior myocardial infarction, or arrhythmia.~6. Symptomatic intrinsic lung disease resulting in dyspnea at rest.~7. Concurrent life-limiting disease with a life expectancy of less than one year.~8. Pregnancy, nursing women, and fertile women who do not practice birth control.~9. Inability to give informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).